Modus Therapeutics Holding AB (OSTO:MODTX) Total Operating Expense: kr18.71 Mil (TTM As of Mar. 2026)


OSTO:MODTX Modus Therapeutics Holding AB OSTO:MODTX
25 GF Score
Price kr0.36
! 1 Warning Sign
View Full Analysis

What is Modus Therapeutics Holding AB Total Operating Expense?

Modus Therapeutics Holding AB OSTO:MODTX -1.90% 25 Total Operating Expense is kr18.71 Mil as of Mar. 2026. GuruFocus rates OSTO:MODTX with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Modus Therapeutics Holding AB's Total Operating Expense for the three months ended in Mar. 2026 was kr3.28 Mil. Modus Therapeutics Holding AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr18.71 Mil.

Modus Therapeutics Holding AB Total Operating Expense Related Terms

Modus Therapeutics Holding AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Modus Therapeutics Holding AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modus Therapeutics Holding AB Total Operating Expense Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 20.69 18.01 16.40 15.84 18.14

Modus Therapeutics Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 5.87 4.23 5.33 3.28
OSTO:MODTX
25GF Score
Modus Therapeutics Holding AB OSTO:MODTX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modus Therapeutics Holding AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr18.71 Mil mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a Total Operating Expense of kr18.71 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Modus Therapeutics Holding AB and its competitors.
Is Modus Therapeutics Holding AB's Total Operating Expense too high?
Modus Therapeutics Holding AB's current Total Operating Expense is kr18.71 Mil. Overall, Modus Therapeutics Holding AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's Total Operating Expense compare to VRTX and REGN?
Modus Therapeutics Holding AB's Total Operating Expense of kr18.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current Total Operating Expense is kr18.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current Total Operating Expense of kr18.71 Mil. The current Total Operating Expense is kr18.71 Mil. Modus Therapeutics Holding AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current Total Operating Expense is kr18.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modus Therapeutics Holding AB Business Description

Address Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
25GF Score

Get the complete analysis for OSTO:MODTX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.36
Price